Literature DB >> 3259873

Adenosine triphosphate can maintain multipotent haemopoietic stem cells in the absence of interleukin 3 via a membrane permeabilization mechanism.

A D Whetton1, S J Huang, P N Monk.   

Abstract

The survival, proliferation and development of haemopoietic stem cells in vitro requires the presence of specific growth factors such as Interleukin 3, in the absence of these growth factors the cells die very rapidly (8-48 hours). Adenosine triphosphate can maintain an Interleukin 3 dependent stem cell line in the absence of this growth factor for periods up to and beyond 48 hours. This effect of ATP is mediated by an increase in plasma membrane permeability. ATP mediated survival will be an important tool in studying both Interleukin 3 dependence of stem cells and also in the study of stem cell differentiation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259873     DOI: 10.1016/s0006-291x(88)80408-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

Review 1.  Purinergic signaling in embryonic and stem cell development.

Authors:  Geoffrey Burnstock; Henning Ulrich
Journal:  Cell Mol Life Sci       Date:  2011-01-08       Impact factor: 9.261

2.  ATP-induced pore formation in the plasma membrane of rat peritoneal mast cells.

Authors:  P E Tatham; M Lindau
Journal:  J Gen Physiol       Date:  1990-03       Impact factor: 4.086

3.  Permeabilization of cells of hemopoietic origin by extracellular ATP4-: elimination of osteoclasts, macrophages, and their precursors from isolated bone cell populations and fetal bone rudiments.

Authors:  W E Modderman; A F Weidema; T Vrijheid-Lammers; A M Wassenaar; P J Nijweide
Journal:  Calcif Tissue Int       Date:  1994-08       Impact factor: 4.333

4.  Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents.

Authors:  M K Collins; J Marvel; P Malde; A Lopez-Rivas
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.